Patient description: 19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain. She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Complicated Urinary Tract Infection Pyelonephritis Provide written informed consent prior to any study-related procedure not part of normal medical care (a legally acceptable representative may provide consent if the subject is unable to do so, provided this is approved by local country and institution specific guidelines). 2. Be males or females ≥ 18 years of age 3. If female, subject is non-lactating, and is either: 1. Not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy, or hysterectomy; or 2. Of childbearing potential and is practicing a barrier method of birth control (e.g., a diaphragm or contraceptive sponge) along with 1 of the following methods: oral or parenteral contraceptives (for 3 months prior to study drug administration), or a vasectomized partner. Or, subject is practicing abstinence from sexual intercourse. Subjects must be willing to practice these methods for the duration of the trial and for at least 35 days after last dose of study medication. 4. Males are required to practice reliable birth control methods (condom or other barrier device) during the conduct of the study and for at least 35 days after last dose of study medication. 5. Pyuria (white blood cell [WBC] count > 10/μL in unspun urine or ≥ 10 per high power field in spun urine). 6. Clinical signs and/or symptoms of cUTI, either of: 1. Pyelonephritis, as indicated by at least 2 of the following Documented fever (oral temperature > 38°C) accompanied by patient symptoms of rigors, chills, or "warmth" Flank pain Costovertebral angle tenderness or suprapubic tenderness on physical exam; or nausea or vomiting; OR 2. Complicated lower UTI, as indicated by at least 2 of the following At least 2 of the following new or worsening symptoms of cUTI Dysuria; urinary frequency or urinary urgency Documented fever (oral temperature > 38°C) accompanied by patient symptoms of rigors, chills, or "warmth" Suprapubic pain or flank pain Costovertebral angle tenderness or suprapubic tenderness on physical exam; or  Have a documented history of any moderate or severe hypersensitivity or allergic reaction to any β-lactam or quinilone antibacterial (Note: for β-lactams, a history of a mild rash followed by uneventful re-exposure is not a contraindication to enrollment) 2. Have a concomitant infection at the time of randomization, which requires non-study systemic antibacterial therapy in addition to IV study drug therapy. (Drugs with only gram-positive activity [e.g., vancomycin, linezolid] are allowed.) 3. Receipt of any amount of potentially therapeutic antibacterial therapy after collection of the pretreatment baseline urine culture and before administration of the first dose of study drug. 4. Receipt of any dose of a potentially therapeutic antibacterial agent for the treatment of the current UTI within 48 hours before the study-qualifying pretreatment baseline urine is obtained (exceptions: subjects with an active cUTI who have received prior antibiotics may be enrolled provided a minimum of 48 hours have elapsed between the last dose of the prior antibiotic and the time of obtaining the baseline urine specimen. Subjects receiving current antibiotic prophylaxis for cUTI who present with signs and symptoms consistent with an active new cUTI may be enrolled provided all other are met including obtaining a pre-treatment qualifying baseline urine culture). 5. Intractable urinary infection at baseline that the Investigator anticipates would require more than 7 days of study drug therapy. 6. Complete, permanent obstruction of the urinary tract. 7. Confirmed fungal urinary tract infection at time of randomization (with ≥ 103 fungal CFU/mL). 8. Permanent indwelling bladder catheter or urinary stent including nephrostomy. 9. Suspected or confirmed perinephric or intrarenal abscess. 10. Suspected or confirmed prostatitis. 11. Ileal loop or known vesico-ureteral reflux. 12. Severe impairment of renal function including an estimated CrCl < 30 mL/min, requirement for peritoneal dialysis, hemodialysis or hemofiltration, or oliguria (< 20 mL/h urine output over 24 hours). 13. Current urinary catheter that is not scheduled to be removed before the EOT (intermittent straight catheterization during the IV study drug administration period is acceptable). 14. Any condition or circumstance that, in the opinion of the Investigator, would compromise the safety of the subject or the quality of study data. 15. Any rapidly progressing disease or immediately life-threatening illness including acute hepatic failure, respiratory failure, and septic shock. 16. Immunocompromising condition, including established AIDS, hematological malignancy, or bone marrow transplantation, or immunosuppressive therapy including cancer chemotherapy, medications for prevention of organ transplantation rejection, or the administration of corticosteroids equivalent to or greater than 40 mg of prednisone per day administered continuously for more than 14 days preceding randomization. 17. One or more of the following laboratory abnormalities in baseline specimens: aspartate aminotransferase (AST [SGOT]), alanine aminotransferase (ALT [SGPT]), alkaline phosphatase, or total bilirubin level greater than 3 times the upper limit of normal (ULN), absolute neutrophil count less than 500/μL, platelet count less than 40,000/μL, or hematocrit less than 20%. 18. Participation in any clinical study of an investigational product within 30 days prior to the proposed first day of study drug. 19. Previous participation in any study of CXA-101 or CXA-201. 20. Women who are pregnant or nursing